A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment

Trial Profile

A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Capmatinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 30 Aug 2016 Status changed from suspended to withdrawn prior to enrolment.
    • 13 Dec 2013 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 13 Dec 2013 Planned initiation date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top